Pretreatment and posttreatment clinical and laboratory data for patients reported to the FDA
| Case . | Age (yr) . | Sex . | Dose (μg/kg) . | Pre-Hg (g/L) . | Hg-uria (days) . | ΔHg (g/dL) . | PRBCs (units) . | ΔSCr (mg/L) . | Patient Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 7 | M | 50 | 120 | — | 30 | 0 | NA | no sequelae |
| 2 | 60 | M | 24 | 149 | ≥7 | 49 | 0 | 25 | recovered |
| 3 | 12 | F | 37 | 100 | — | NA | — | 36*,† | died‡ |
| 4 | 40 | F | 52 | 102 | ≥7 | NA | 5 | NA | recovered |
| 5 | 60 | M | 52 | 95 | — | NA | 1 | 19 | recovered |
| 6 | 86 | F | 46 | 91 | — | 37 | 01-153 | NA | died1-155 |
| 7 | 32 | F | 29 | 106 | — | NA | 6 | 10* | recovered |
| 8 | 3 | M | 53 | 134 | ≤1 | 27 | 0 | NA | no sequelae |
| 9 | 17 | F | 49 | 145 | ≥3 | 60 | 0 | 47 | recovered |
| 10 | 72 | F | 59 | 105 | ≥2 | NA | 2 | NA | died‡ |
| 11 | 16 | F | 100 | 127 | ≥20 | 76 | 0 | NA | no sequelae |
| 12 | 9 | M | 25 | 119 | ≤1 | 00 | 0 | NA | no sequelae |
| 13 | 82 | F | 75 | 99 | ≥2 | NA | 2 | 8 | died‡ |
| 14 | 14 | F | 50 | 125 | — | NA | 1 | 103† | recovered |
| 15 | 41 | M | 53 | 141 | NA | 14 | 0 | — | recovered |
| Case . | Age (yr) . | Sex . | Dose (μg/kg) . | Pre-Hg (g/L) . | Hg-uria (days) . | ΔHg (g/dL) . | PRBCs (units) . | ΔSCr (mg/L) . | Patient Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 7 | M | 50 | 120 | — | 30 | 0 | NA | no sequelae |
| 2 | 60 | M | 24 | 149 | ≥7 | 49 | 0 | 25 | recovered |
| 3 | 12 | F | 37 | 100 | — | NA | — | 36*,† | died‡ |
| 4 | 40 | F | 52 | 102 | ≥7 | NA | 5 | NA | recovered |
| 5 | 60 | M | 52 | 95 | — | NA | 1 | 19 | recovered |
| 6 | 86 | F | 46 | 91 | — | 37 | 01-153 | NA | died1-155 |
| 7 | 32 | F | 29 | 106 | — | NA | 6 | 10* | recovered |
| 8 | 3 | M | 53 | 134 | ≤1 | 27 | 0 | NA | no sequelae |
| 9 | 17 | F | 49 | 145 | ≥3 | 60 | 0 | 47 | recovered |
| 10 | 72 | F | 59 | 105 | ≥2 | NA | 2 | NA | died‡ |
| 11 | 16 | F | 100 | 127 | ≥20 | 76 | 0 | NA | no sequelae |
| 12 | 9 | M | 25 | 119 | ≤1 | 00 | 0 | NA | no sequelae |
| 13 | 82 | F | 75 | 99 | ≥2 | NA | 2 | 8 | died‡ |
| 14 | 14 | F | 50 | 125 | — | NA | 1 | 103† | recovered |
| 15 | 41 | M | 53 | 141 | NA | 14 | 0 | — | recovered |
Data are given for pretreatment hemoglobin (pre-Hg), hemoglobinuria (Hg-uria), and the maximum difference between pretreatment and posttreatment hemoglobins in patients who were not transfused with PRBCs (ΔHg). The term PRBCs indicates units of PRBCs transfused. ΔSCr indicates maximum difference between pretreatment and posttreatment serum creatinine levels in patients who experienced renal insufficiency. NA indicates not applicable.
Preexisting renal insufficiency.
Patient underwent renal dialysis.
Primary cause of death due to underlying disease.
PRBCs ordered but patient refused transfusion.
Primary cause of death due to complications of posttreatment sequelae.